PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 213/82, 307/68, 333/38, 409/04, 263/34, 277/20, 417/02, 333/70, 307/84, 215/48, 231/14, 241/44, 249/06, 307/91, 401/04

A1

(11) International Publication Number: **WO 00/18738**

(43) International Publication Date: 6 April 2000 (06.04.00)

(21) International Application Number: PCT/GB99/03144

(22) International Filing Date: 21 September 1999 (21.09.99)

(30) Priority Data:

9820770.7	25 September 1998 (25.09.98)	GB
9826938.4	9 December 1998 (09.12.98)	GB
9905969.3	17 March 1999 (17.03.99)	GB

(71) Applicant *(for all designated States except US)*: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: BROWN, Dearg, Sutherland [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). BROWN, George, Robert [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: TAIT, Brian, Steele; AstraZeneca PLC, Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS



(I)

(57) Abstract

The invention concerns amide derivatives of formula (I) wherein R^3 is (1–6C)alkyl or halogeno; m is 0–3, p is 0–2 and q is 0–4; each of R^1 and R^2 is a group such as hydroxy, halogeno, trifluoromethyl and cyano; R^4 is a basic group such as amino, (1–6C)alkylamino, di–[(1–6C)alkyl]amino, di–[(1–6C)alkyl]amino–(1–6C)alkyl, di–[(1–6C)alkyl]amino–(2–6C)alkoxy, heteroaryl, heteroaryloxy, heteroaryl–(1–6C)alkoxy, heterocyclyl, heterocyclyloxy and heterocyclyl–(1–6C)alkoxy; and Q^2 is a group such as heteroaryl, heteroaryloxy or heteroaryl–(1–6C)alkoxy which is optionally substituted; or pharmaceutically–acceptable salts or in–vivo–cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.